{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T05:10:11Z","timestamp":1788930611707,"version":"build-2803163510"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"DOI":"10.1007\/s10741-026-10677-5","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T03:20:56Z","timestamp":1788924056000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Tolvaptan in heart failure: Contemporary evidence and a framework for precision decongestion"],"prefix":"10.1007","volume":"31","author":[{"given":"Teruhiko","family":"Imamura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"issue":"12","key":"10677_CR1","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1038\/s41569-025-01152-z","volume":"22","author":"ZL Cox","year":"2025","unstructured":"Cox ZL, Damman K, Testani JM (2025) Decongestion in heart failure: medical and device therapies. Nat Rev Cardiol 22(12):961\u2013977","journal-title":"Nat Rev Cardiol"},{"key":"10677_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2025.02.014","author":"T Kitai","year":"2025","unstructured":"Kitai T, Kohsaka S, Kato T, Kato E, Sato K, Teramoto K, Yaku H, Akiyama E, Ando M, Izumi C, Ide T, Iwasaki YK, Ohno Y, Okumura T, Ozasa N, Kaji S, Kashimura T, Kitaoka H, Kinugasa Y, Kinugawa S, Toda K, Nagai T, Nakamura M, Hikoso S, Minamisawa M, Wakasa S, Anchi Y, Oishi S, Okada A, Obokata M, Kagiyama N, Kato NP, Kohno T, Sato T, Shiraishi Y, Tamaki Y, Tamura Y, Nagao K, Nagatomo Y, Nakamura N, Nochioka K, Nomura A, Nomura S, Horiuchi Y, Mizuno A, Murai R, Inomata T, Kuwahara K, Sakata Y, Tsutsui H, Kinugawa K, Japanese Circulation S, the Japanese Heart Failure Society Joint Working G (2025) JCS\/JHFS 2025 guideline on diagnosis and treatment of heart failure. J Card Fail. https:\/\/doi.org\/10.1016\/j.cardfail.2025.02.014","journal-title":"J Card Fail"},{"issue":"37","key":"10677_CR3","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","volume":"44","author":"TA McDonagh","year":"2023","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, Burri H, Butler J, Celutkiene J, Chioncel O, Cleland JGF, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Skibelund AK, Group ESCSD (2023) 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 44(37):3627\u20133639","journal-title":"Eur Heart J"},{"issue":"18","key":"10677_CR4","first-page":"e895","volume":"145","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW, Members AAJC (2022) 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 145(18):e895\u2013e1032","journal-title":"Circulation"},{"key":"10677_CR5","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.15420\/cfr.2024.07","volume":"10","author":"M Kumric","year":"2024","unstructured":"Kumric M, Kurir TT, Bozic J, Slujo AB, Glavas D, Miric D, Lozo M, Zanchi J, Borovac JA (2024) Pathophysiology of Congestion in Heart Failure: A Contemporary Review. Card Fail Rev 10:e13","journal-title":"Card Fail Rev"},{"issue":"10","key":"10677_CR6","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/s41569-020-0379-7","volume":"17","author":"EM Boorsma","year":"2020","unstructured":"Boorsma EM, Ter Maaten JM, Damman K, Dinh W, Gustafsson F, Goldsmith S, Burkhoff D, Zannad F, Udelson JE, Voors AA (2020) Congestion in heart failure: a contemporary look at physiology, diagnosis and treatment. Nat Rev Cardiol 17(10):641\u201355","journal-title":"Nat Rev Cardiol"},{"issue":"17","key":"10677_CR7","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1161\/CIRCULATIONAHA.119.039920","volume":"140","author":"S Selvaraj","year":"2019","unstructured":"Selvaraj S, Claggett B, Pozzi A, McMurray JJV, Jhund PS, Packer M, Desai AS, Lewis EF, Vaduganathan M, Lefkowitz MP, Rouleau JL, Shi VC, Zile MR, Swedberg K, Solomon SD (2019) Prognostic Implications of Congestion on Physical Examination Among Contemporary Patients With Heart Failure and Reduced Ejection Fraction: PARADIGM-HF. Circulation 140(17):1369\u20131379","journal-title":"Circulation"},{"issue":"2","key":"10677_CR8","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/ejhf.1369","volume":"21","author":"W Mullens","year":"2019","unstructured":"Mullens W, Damman K, Harjola VP, Mebazaa A, Brunner-La Rocca HP, Martens P, Testani JM, Tang WHW, Orso F, Rossignol P, Metra M, Filippatos G, Seferovic PM, Ruschitzka F, Coats AJ (2019) The use of diuretics in heart failure with congestion - a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 21(2):137\u201355","journal-title":"Eur J Heart Fail"},{"issue":"20","key":"10677_CR9","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1056\/NEJMra1703100","volume":"377","author":"DH Ellison","year":"2017","unstructured":"Ellison DH, Felker GM (2017) Diuretic Treatment in Heart Failure. N Engl J Med 377(20):1964\u20131975","journal-title":"N Engl J Med"},{"issue":"2","key":"10677_CR10","doi-asserted-by":"publisher","first-page":"F273","DOI":"10.1152\/ajprenal.00195.2005","volume":"290","author":"LC Costello-Boerrigter","year":"2006","unstructured":"Costello-Boerrigter LC, Smith WB, Boerrigter G, Ouyang J, Zimmer CA, Orlandi C, Burnett JC Jr. (2006) Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. Am J Physiol Renal Physiol 290(2):F273-8","journal-title":"Am J Physiol Renal Physiol"},{"issue":"12","key":"10677_CR11","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1177\/0091270007307877","volume":"47","author":"SE Shoaf","year":"2007","unstructured":"Shoaf SE, Wang Z, Bricmont P, Mallikaarjun S (2007) Pharmacokinetics, pharmacodynamics, and safety of tolvaptan, a nonpeptide AVP antagonist, during ascending single-dose studies in healthy subjects. J Clin Pharmacol 47(12):1498\u20131507","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"10677_CR12","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.jjcc.2018.10.003","volume":"73","author":"T Imamura","year":"2019","unstructured":"Imamura T, Kinugawa K (2019) Update of acute and long-term tolvaptan therapy. J Cardiol 73(2):102\u2013107","journal-title":"J Cardiol"},{"issue":"12","key":"10677_CR13","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1001\/jama.297.12.1319","volume":"297","author":"MA Konstam","year":"2007","unstructured":"Konstam MA, Gheorghiade M, Burnett JC Jr., Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C (2007) Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan I. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 297(12):1319\u20131331","journal-title":"JAMA"},{"key":"10677_CR14","doi-asserted-by":"crossref","unstructured":"Nakamura M, Imamura T, Kinugawa K (2024) Preliminary report of intravenous tolvaptan sodium phosphate (Samtas((R))) treatment in decompensated heart failure. J Clin Med 13(3)","DOI":"10.3390\/jcm13030720"},{"issue":"5","key":"10677_CR15","doi-asserted-by":"publisher","first-page":"3275","DOI":"10.1002\/ehf2.14021","volume":"9","author":"N Sato","year":"2022","unstructured":"Sato N, Uno S, Kurita Y, Kim S, Investigators O-H (2022) Efficacy and safety of intravenous OPC-61815 compared with oral tolvaptan in patients with congestive heart failure. ESC Heart Fail 9(5):3275\u201386","journal-title":"ESC Heart Fail"},{"issue":"1","key":"10677_CR16","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1161\/CIRCHEARTFAILURE.112.970012","volume":"6","author":"DE Lanfear","year":"2013","unstructured":"Lanfear DE, Sabbah HN, Goldsmith SR, Greene SJ, Ambrosy AP, Fought AJ, Kwasny MJ, Swedberg K, Yancy CW, Konstam MA, Maggioni AP, Zannad F, Gheorghiade M, investigators Et (2013) Association of arginine vasopressin levels with outcomes and the effect of V2 blockade in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial. Circ Heart Fail 6(1):47\u201352","journal-title":"Circ Heart Fail"},{"issue":"5","key":"10677_CR17","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.jacc.2014.12.010","volume":"65","author":"FH Verbrugge","year":"2015","unstructured":"Verbrugge FH, Steels P, Grieten L, Nijst P, Tang WH, Mullens W (2015) Hyponatremia in acute decompensated heart failure: depletion versus dilution. J Am Coll Cardiol 65(5):480\u2013492","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10677_CR18","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s10157-013-0789-5","volume":"17","author":"JL Wilson","year":"2013","unstructured":"Wilson JL, Miranda CA, Knepper MA (2013) Vasopressin and the regulation of aquaporin-2. Clin Exp Nephrol 17(6):751\u2013764","journal-title":"Clin Exp Nephrol"},{"issue":"21","key":"10677_CR19","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.1161\/01.CIR.0000070422.41439.04","volume":"107","author":"M Gheorghiade","year":"2003","unstructured":"Gheorghiade M, Niazi I, Ouyang J, Czerwiec F, Kambayashi J, Zampino M, Orlandi C, Tolvaptan I (2003) Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation 107(21):2690\u20132696","journal-title":"Circulation"},{"issue":"7","key":"10677_CR20","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1681\/ASN.2006030240","volume":"17","author":"RW Schrier","year":"2006","unstructured":"Schrier RW (2006) Body water homeostasis: clinical disorders of urinary dilution and concentration. J Am Soc Nephrol 17(7):1820\u20131832","journal-title":"J Am Soc Nephrol"},{"issue":"16","key":"10677_CR21","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1001\/jama.291.16.1963","volume":"291","author":"M Gheorghiade","year":"2004","unstructured":"Gheorghiade M, Gattis WA, O\u2019Connor CM, Adams KF Jr., Elkayam U, Barbagelata A, Ghali JK, Benza RL, McGrew FA, Klapholz M, Ouyang J, Orlandi C (2004) Acute, Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive Heart Failure I. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA 291(16):1963\u20131971","journal-title":"JAMA"},{"issue":"12","key":"10677_CR22","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1001\/jama.297.12.1332","volume":"297","author":"M Gheorghiade","year":"2007","unstructured":"Gheorghiade M, Konstam MA, Burnett JC Jr., Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C (2007) Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan I. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA 297(12):1332\u20131343","journal-title":"JAMA"},{"issue":"22","key":"10677_CR23","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1016\/j.jacc.2007.01.091","volume":"49","author":"JE Udelson","year":"2007","unstructured":"Udelson JE, McGrew FA, Flores E, Ibrahim H, Katz S, Koshkarian G, O\u2019Brien T, Kronenberg MW, Zimmer C, Orlandi C, Konstam MA (2007) Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction. J Am Coll Cardiol 49(22):2151\u20132159","journal-title":"J Am Coll Cardiol"},{"issue":"Suppl 1","key":"10677_CR24","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1007\/s10557-011-6304-x","volume":"25","author":"M Matsuzaki","year":"2011","unstructured":"Matsuzaki M, Hori M, Izumi T, Fukunami M, Tolvaptan I (2011) Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: a phase III, randomized, double-blind, placebo-controlled study (QUEST study). Cardiovasc Drugs Ther 25(Suppl 1):S33\u201345","journal-title":"Cardiovasc Drugs Ther"},{"issue":"3","key":"10677_CR25","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1002\/ehf2.12088","volume":"3","author":"K Jujo","year":"2016","unstructured":"Jujo K, Saito K, Ishida I, Furuki Y, Kim A, Suzuki Y, Sekiguchi H, Yamaguchi J, Ogawa H, Hagiwara N (2016) Randomized pilot trial comparing tolvaptan with furosemide on renal and neurohumoral effects in acute heart failure. ESC Heart Fail 3(3):177\u2013188","journal-title":"ESC Heart Fail"},{"issue":"6","key":"10677_CR26","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.cardfail.2016.02.007","volume":"22","author":"Y Matsue","year":"2016","unstructured":"Matsue Y, Suzuki M, Torii S, Yamaguchi S, Fukamizu S, Ono Y, Fujii H, Kitai T, Nishioka T, Sugi K, Onishi Y, Noda M, Kagiyama N, Satoh Y, Yoshida K, Goldsmith SR (2016) Clinical Effectiveness of Tolvaptan in Patients With Acute Heart Failure and Renal Dysfunction. J Card Fail 22(6):423\u2013432","journal-title":"J Card Fail"},{"issue":"11","key":"10677_CR27","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/j.jacc.2016.09.004","volume":"69","author":"GM Felker","year":"2017","unstructured":"Felker GM, Mentz RJ, Cole RT, Adams KF, Egnaczyk GF, Fiuzat M, Patel CB, Echols M, Khouri MG, Tauras JM, Gupta D, Monds P, Roberts R, O\u2019Connor CM (2017) Efficacy and Safety of Tolvaptan in Patients Hospitalized With Acute Heart Failure. J Am Coll Cardiol 69(11):1399\u20131406","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"10677_CR28","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1016\/j.jacc.2016.12.035","volume":"69","author":"MA Konstam","year":"2017","unstructured":"Konstam MA, Kiernan M, Chandler A, Dhingra R, Mody FV, Eisen H, Haught WH, Wagoner L, Gupta D, Patten R, Gordon P, Korr K, Fileccia R, Pressler SJ, Gregory D, Wedge P, Dowling D, Romeling M, Konstam JM, Massaro JM, Udelson JE, Secret of Chf Investigators C, Committee M (2017) Short-term effects of tolvaptan in patients with acute heart failure and volume overload. J Am Coll Cardiol 69(11):1409\u201319","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10677_CR29","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1253\/circj.CJ-17-0179","volume":"82","author":"T Inomata","year":"2017","unstructured":"Inomata T, Ikeda Y, Kida K, Shibagaki Y, Sato N, Kumagai Y, Shinagawa H, Ako J, Izumi T, Kanagawa Aquaresis I (2017) Effects of Additive Tolvaptan vs. Increased Furosemide on Heart Failure With Diuretic Resistance and Renal Impairment\u3000- Results From the K-STAR Study. Circ J 82(1):159\u2013167","journal-title":"Circ J"},{"issue":"3","key":"10677_CR30","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.jchf.2019.09.012","volume":"8","author":"ZL Cox","year":"2020","unstructured":"Cox ZL, Hung R, Lenihan DJ, Testani JM (2020) Diuretic Strategies for Loop Diuretic Resistance in Acute Heart Failure: The 3T Trial. JACC Heart Fail 8(3):157\u2013168","journal-title":"JACC Heart Fail"},{"issue":"6","key":"10677_CR31","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.cardfail.2013.04.001","volume":"19","author":"PJ Hauptman","year":"2013","unstructured":"Hauptman PJ, Burnett J, Gheorghiade M, Grinfeld L, Konstam MA, Kostic D, Krasa HB, Maggioni A, Ouyang J, Swedberg K, Zannad F, Zimmer C, Udelson JE, Everest I (2013) Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptan. J Card Fail 19(6):390\u2013397","journal-title":"J Card Fail"},{"issue":"5","key":"10677_CR32","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1536\/ihj.16-023","volume":"57","author":"T Imamura","year":"2016","unstructured":"Imamura T, Kinugawa K (2016) Tolvaptan Improves the Long-Term Prognosis in Patients With Congestive Heart Failure With Preserved Ejection Fraction as Well as in Those With Reduced Ejection Fraction. Int Heart J 57(5):600\u2013606","journal-title":"Int Heart J"},{"issue":"5","key":"10677_CR33","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1536\/ihj.16-007","volume":"57","author":"T Imamura","year":"2016","unstructured":"Imamura T, Kinugawa K, Nitta D, Komuro I (2016) Tolvaptan Reduces Long-Term Total Medical Expenses and Length of Stay in Aquaporin-Defined Responders. Int Heart J 57(5):593\u2013599","journal-title":"Int Heart J"},{"issue":"11","key":"10677_CR34","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1253\/circj.CJ-17-0554","volume":"81","author":"Y Uemura","year":"2017","unstructured":"Uemura Y, Shibata R, Takemoto K, Uchikawa T, Koyasu M, Ishikawa S, Imai R, Ozaki Y, Watanabe T, Teraoka T, Watarai M, Murohara T (2017) Safety and Efficacy of Long-Term Use of Tolvaptan in Patients With Heart Failure and Chronic Kidney Disease. Circ J 81(11):1736\u20131738","journal-title":"Circ J"},{"issue":"10","key":"10677_CR35","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1253\/circrep.CR-19-0064","volume":"1","author":"T Imamura","year":"2019","unstructured":"Imamura T, Kinugawa S, Muramatsu T, Shiga T, Ogimoto A, Anzai T, Hagiwara N, Tsutsui H, Komuro I, Kinugawa K (2019) Long-Term Tolvaptan Treatment in Refractory Heart Failure. Circ Rep 1(10):431\u2013437","journal-title":"Circ Rep"},{"issue":"20","key":"10677_CR36","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1056\/NEJMoa065181","volume":"355","author":"RW Schrier","year":"2006","unstructured":"Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, Orlandi C, Investigators S (2006) Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 355(20):2099\u2013112","journal-title":"N Engl J Med"},{"issue":"2","key":"10677_CR37","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1536\/ihj.13-221","volume":"55","author":"T Imamura","year":"2014","unstructured":"Imamura T, Kinugawa K, Minatsuki S, Muraoka H, Kato N, Inaba T, Maki H, Hatano M, Yao A, Komuro I (2014) Urine sodium excretion after tolvaptan administration is dependent upon baseline serum sodium levels: a possible explanation for the improvement of hyponatremia with scarce chance of hypernatremia by a vasopressin receptor antagonist. Int Heart J 55(2):131\u2013137","journal-title":"Int Heart J"},{"issue":"2","key":"10677_CR38","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s00228-024-03778-3","volume":"81","author":"A Kumar","year":"2025","unstructured":"Kumar A, Iqbal U, Amin SB, Arsal SA, Ali SMS, Shafique MA, Shahid MS, Naz A, Asuka ES (2025) Evaluating the safety and effectiveness of tolvaptan in patients with heart failure and renal impairment: a systematic review and meta-analysis. Eur J Clin Pharmacol 81(2):203\u2013216","journal-title":"Eur J Clin Pharmacol"},{"issue":"10","key":"10677_CR39","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1002\/clc.23889","volume":"45","author":"W Shang","year":"2022","unstructured":"Shang W, Zhang Y, Han D (2022) Benefits of tolvaptan on early dyspnea relief in patients with acute heart failure: A meta-analysis. Clin Cardiol 45(10):995\u20131001","journal-title":"Clin Cardiol"},{"key":"10677_CR40","doi-asserted-by":"publisher","first-page":"1367442","DOI":"10.3389\/fcvm.2024.1367442","volume":"11","author":"V Pratama","year":"2024","unstructured":"Pratama V, Budiono J, Thobari JA, Widyantoro B, Anggraeni VY, Dinarti LK (2024) The role of tolvaptan add-on therapy in patients with acute heart failure: a systematic review and network meta-analysis. Front Cardiovasc Med 11:1367442","journal-title":"Front Cardiovasc Med"},{"issue":"9","key":"10677_CR41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0184380","volume":"12","author":"MY Wu","year":"2017","unstructured":"Wu MY, Chen TT, Chen YC, Tarng DC, Wu YC, Lin HH, Tu YK (2017) Effects and safety of oral tolvaptan in patients with congestive heart failure: a systematic review and network meta-analysis. PLoS One 12(9):e0184380","journal-title":"PLoS One"},{"issue":"2","key":"10677_CR42","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1253\/circj.CJ-12-0971","volume":"77","author":"T Imamura","year":"2013","unstructured":"Imamura T, Kinugawa K, Shiga T, Kato N, Muraoka H, Minatsuki S, Inaba T, Maki H, Hatano M, Yao A, Kyo S, Nagai R (2013) Novel criteria of urine osmolality effectively predict response to tolvaptan in decompensated heart failure patients\u2013association between non-responders and chronic kidney disease. Circ J 77(2):397\u2013404","journal-title":"Circ J"},{"issue":"5","key":"10677_CR43","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1253\/circj.CJ-12-1328","volume":"77","author":"T Imamura","year":"2013","unstructured":"Imamura T, Kinugawa K, Minatsuki S, Muraoka H, Kato N, Inaba T, Maki H, Shiga T, Hatano M, Yao A, Kyo S, Komuro I (2013) Urine osmolality estimated using urine urea nitrogen, sodium and creatinine can effectively predict response to tolvaptan in decompensated heart failure patients. Circ J 77(5):1208\u201313","journal-title":"Circ J"},{"issue":"9","key":"10677_CR44","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1253\/circj.CJ-14-0244","volume":"78","author":"T Imamura","year":"2014","unstructured":"Imamura T, Kinugawa K, Fujino T, Inaba T, Maki H, Hatano M, Yao A, Komuro I (2014) Increased urine aquaporin-2 relative to plasma arginine vasopressin is a novel marker of response to tolvaptan in patients with decompensated heart failure. Circ J 78(9):2240\u20132249","journal-title":"Circ J"},{"issue":"5","key":"10677_CR45","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s10157-023-02325-1","volume":"27","author":"K Kakeshita","year":"2023","unstructured":"Kakeshita K, Koike T, Imamura T, Fujioka H, Yamazaki H, Kinugawa K (2023) Impact of urine cyclic AMP relative to plasma arginine vasopressin on response to tolvaptan in patients with chronic kidney disease and heart failure. Clin Exp Nephrol 27(5):427\u2013434","journal-title":"Clin Exp Nephrol"},{"issue":"3","key":"10677_CR46","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1007\/s00380-018-1270-x","volume":"34","author":"Y Ikeda","year":"2019","unstructured":"Ikeda Y, Inomata T, Kida K, Shibagaki Y, Sato N, Izumi T, Ako J, Kanagawa Aquaresis I (2019) Different diuretic properties between tolvaptan and furosemide in congestive heart failure patients with diuretic resistance and renal impairment: a subanalysis of the K-STAR. Heart Vessels 34(3):442\u201351","journal-title":"Heart Vessels"},{"issue":"4","key":"10677_CR47","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.jacc.2008.03.050","volume":"52","author":"S Neuhold","year":"2008","unstructured":"Neuhold S, Huelsmann M, Strunk G, Stoiser B, Struck J, Morgenthaler NG, Bergmann A, Moertl D, Berger R, Pacher R (2008) Comparison of copeptin, B-type natriuretic peptide, and amino-terminal pro-B-type natriuretic peptide in patients with chronic heart failure: prediction of death at different stages of the disease. J Am Coll Cardiol 52(4):266\u2013272","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10677_CR48","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1536\/ihj.15-491","volume":"57","author":"M Kadota","year":"2016","unstructured":"Kadota M, Ise T, Yagi S, Iwase T, Akaike M, Ueno R, Kawabata Y, Hara T, Ogasawara K, Bando M, Bando S, Matsuura T, Yamaguchi K, Yamada H, Soeki T, Wakatsuki T, Sata M (2016) Response Prediction and Influence of Tolvaptan in Chronic Heart Failure Patients Considering the Interaction of the Renin-Angiotensin-Aldosterone System and Arginine Vasopressin. Int Heart J 57(4):461\u2013465","journal-title":"Int Heart J"},{"issue":"4","key":"10677_CR49","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1007\/s00380-017-1072-6","volume":"33","author":"T Kogure","year":"2018","unstructured":"Kogure T, Jujo K, Hamada K, Saito K, Hagiwara N (2018) Good response to tolvaptan shortens hospitalization in patients with congestive heart failure. Heart Vessels 33(4):374\u2013383","journal-title":"Heart Vessels"},{"issue":"7","key":"10677_CR50","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1253\/circj.CJ-21-0926","volume":"86","author":"K Kinugawa","year":"2022","unstructured":"Kinugawa K, Nakata E, Hirano T, Kim S (2022) Tolerability of the Intravenously Administered Tolvaptan Prodrug, OPC-61815, in Patients With Congestive Heart Failure Who Have Difficulty With, or Are Incapable of, Oral Intake (TRITON-HF) - A Phase III, Multicenter, Open-Label Trial. Circ J 86(7):1068\u20131078","journal-title":"Circ J"},{"issue":"4","key":"10677_CR51","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1253\/circj.CJ-21-0430","volume":"86","author":"N Sato","year":"2022","unstructured":"Sato N, Uno S, Yamasaki Y, Hirano T, Kim S, Investigators OPC (2022) Pharmacokinetics, pharmacodynamics, efficacy, and safety of OPC-61815, a prodrug of tolvaptan for intravenous administration, in patients with congestive heart failure - a phase II, multicenter, double-blind, randomized, active-controlled trial. Circ J 86(4):699\u2013708","journal-title":"Circ J"},{"issue":"8","key":"10677_CR52","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/j.hlc.2017.12.013","volume":"27","author":"J Sen","year":"2018","unstructured":"Sen J, Chung E, McGill D (2018) Tolvaptan for Heart Failure in Chronic Kidney Disease Patients: A Systematic Review and Meta-Analysis. Heart Lung Circ 27(8):928\u2013939","journal-title":"Heart Lung Circ"},{"issue":"3","key":"10677_CR53","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1097\/MAT.0000000000001079","volume":"66","author":"T Fujino","year":"2020","unstructured":"Fujino T, Imamura T, Nguyen A, Chung B, Raikhelkar J, Rodgers D, Nitta D, Smith B, Sarswat N, Kalantari S, Narang N, LaBuhn C, Jeevanandam V, Kim G, Sayer G, Uriel N (2020) Short-Term Efficacy and Safety of Tolvaptan in Patients with Left Ventricular Assist Devices. ASAIO J 66(3):253\u2013257","journal-title":"ASAIO J"},{"issue":"12","key":"10677_CR54","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1111\/aor.14375","volume":"46","author":"MN Belkin","year":"2022","unstructured":"Belkin MN, Imamura T, Rodgers D, Kanelidis AJ, Henry MP, Fujino T, Kagan V, Meehan K, Okray J, Creighton S, LaBuhn C, Song T, Ota T, Jeevanandam V, Nguyen AB, Chung BB, Smith BA, Kalantari S, Grinstein J, Sarswat N, Pinney SP, Sayer G, Kim G, Uriel N (2022) Postoperative tolvaptan use in left ventricular assist device patients: The TOLVAD randomized pilot study. Artif Organs 46(12):2382\u20132390","journal-title":"Artif Organs"},{"issue":"5","key":"10677_CR55","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1253\/circj.CJ-16-1122","volume":"81","author":"S Tamaki","year":"2017","unstructured":"Tamaki S, Sato Y, Yamada T, Morita T, Furukawa Y, Iwasaki Y, Kawasaki M, Kikuchi A, Kondo T, Ozaki T, Seo M, Ikeda I, Fukuhara E, Abe M, Nakamura J, Fukunami M (2017) Tolvaptan Reduces the Risk of Worsening Renal Function in Patients With Acute Decompensated Heart Failure and Preserved Left Ventricular Ejection Fraction\u3000- Prospective Randomized Controlled Study. Circ J 81(5):740\u2013747","journal-title":"Circ J"},{"key":"10677_CR56","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.ijcard.2018.01.067","volume":"258","author":"J Rubio-Gracia","year":"2018","unstructured":"Rubio-Gracia J, Demissei BG, Ter Maaten JM, Cleland JG, O\u2019Connor CM, Metra M, Ponikowski P, Teerlink JR, Cotter G, Davison BA, Givertz MM, Bloomfield DM, Dittrich H, Damman K, Perez-Calvo JI, Voors AA (2018) Prevalence, predictors and clinical outcome of residual congestion in acute decompensated heart failure. Int J Cardiol 258:185\u2013191","journal-title":"Int J Cardiol"},{"issue":"4","key":"10677_CR57","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.jchf.2017.09.023","volume":"6","author":"N Girerd","year":"2018","unstructured":"Girerd N, Seronde MF, Coiro S, Chouihed T, Bilbault P, Braun F, Kenizou D, Maillier B, Nazeyrollas P, Roul G, Fillieux L, Abraham WT, Januzzi J Jr., Sebbag L, Zannad F, Mebazaa A, Rossignol P, the EFHFG (2018) Integrative Assessment of Congestion in Heart Failure Throughout the Patient Journey. JACC Heart Fail 6(4):273\u2013285","journal-title":"JACC Heart Fail"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-026-10677-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10741-026-10677-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-026-10677-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T05:03:15Z","timestamp":1788930195000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10741-026-10677-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["10677"],"URL":"https:\/\/doi.org\/10.1007\/s10741-026-10677-5","relation":{},"ISSN":["1573-7322"],"issn-type":[{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,9]]},"assertion":[{"value":"16 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Human Ethics and Consent to Participate declarations: not applicable.","order":1,"name":"Ethics","label":"Human ethics and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"105"}}